Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Non-Hodgkin 6Recurrence 4Lymphoma 4Leukemia 4Lymphoma, Follicular 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Prolymphocytic, T-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 149Rituximab 104Peripheral Blood Stem Cell Transplantation 101fludarabine phosphate 100Filgrastim 72Mycophenolic Acid 67Cyclosporine 59Radiotherapy 58Whole-Body Irradiation 57Etoposide 55Tacrolimus 51Busulfan 50Antilymphocyte Serum 43Melphalan 41Methotrexate 37Cytarabine 27Cord Blood Stem Cell Transplantation 26fludarabine 25Bortezomib 24Methylprednisolone 23Carmustine 22sargramostim 21Flow Cytometry 19Dexamethasone 19Lenalidomide 18Granulocyte Colony-Stimulating Factor 18Vincristine 17Prednisone 17Bendamustine Hydrochloride 17aldesleukin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Follicular × duvelisib × Other hematologic neoplasm × Clear all
NCT05923502 2023-10-23

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Ruijin Hospital

Not yet recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone

NCT02576275 2021-03-17

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

SecuraBio

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04342117 2021-03-17

REAL

SecuraBio

Terminated
2 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡